According to a regulatory filing, Penumbra (PEN) and Boston Scientific (BSX) each filed a notification and report form under the HSR Act with the DOJ and the FTC on February 13, 2026. On March 16, 2026, Penumbra and Boston Scientific each received a Second Request from the FTC in connection with the FTC’s review of the Merger. The issuance of the Second Request extends the waiting period under the HSR Act until 30 days after both Penumbra and Boston Scientific have substantially complied with the Second Request, unless the waiting period is extended voluntarily by the parties or terminated earlier by the FTC. Penumbra and Boston Scientific expect to promptly respond to the Second Request and to continue to work cooperatively with the FTC in its review of the Merger.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- Private Markets: Kraken pauses IPO plans, Quince raises $500M
- Hold Rating Maintained on Penumbra Amid Strong Results but Limited Visibility Ahead of Boston Scientific Acquisition
- Penumbra price target raised to $360 from $340 at Evercore ISI
- Penumbra trading resumes
- Penumbra reports Q4 adjusted EPS $1.18, consensus $1.11
